Pompano Beach, FL, April 14th, 2020 — BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), and a certified full-service GMP contract development and manufacturing organization, with a focus in perinatal tissue-based medical products, today announced that it had launched a new website at www.BioStemLifeSciences.com. [Read more…]
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
As of today, 41 laboratory COVID-19 diagnostic tests have been authorized by regulators to identify the virus. In the U.S., these tests are supplied by the CDC for the state and local public health departments and private medical providers are getting tests developed by the commercial manufacturers. The U.S. government did not issue guidance allowing commercial labs to process COVID-19 tests until February 29, 2020, after which the companies began testing within a week.
Currently, 20 COVID-19 diagnostic kits from the U.S. manufacturers have won the emergency use authorization (EUA) from the FDA. [Read more…]
Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production.
Bordeaux, France, February 5, 2020 – TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, today announces the appointment of 2 senior executives and 2 independent board members. Pascale Berthet, formerly Business Development Manager at FUJIFILM Cellular Dynamics was appointed Chief Business Development Officer, and Michaël Lanero Fidalgo, former Head of EMEA Biodevelopment Center at Merck KGaA, was recruited as Chief Operating Officer. In addition, 2 independent board members joined TreeFrog Therapeutics’ corporate governance: Julia Berretta, formerly VP of Business Development at Cellectis, and Frederic Desdouits, former Bionest Partner and Pierre Fabre North America director. [Read more…]
With exosome companies rapidly populating in recent years, some of the companies have been working closely with the U.S. FDA to get a specific IND for each clinical condition. Other exosome companies have not and have been supplying their exosome products to consumers without regulatory oversight, despite the FDA being very clear that exosomes are now under their purview.
The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.
For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.
Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]